uPA/PAI-1 expression and uPA promoter methylation in meningiomas

Journal of Neuro-Oncology

Volumn 103, Issue 3, 2011, Pages 533-539

  Kandenwein, Julia Annabel ^a   Park Simon, Tjoung Won ^b   Schramm, Johannes ^a   Simon, Matthias ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Meningiomas; Methylation; PAI 1; Prognosis; uPA

Indexed keywords

BISULFITE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR MARKER; UROKINASE;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER GRADING; CANCER SURVIVAL; DISEASE ASSOCIATION; DNA METHYLATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; MENINGIOMA; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN METHYLATION; TUMOR GROWTH; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; METHYLATION; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROMOTER REGIONS, GENETIC; RETROSPECTIVE STUDIES; STATISTICS AS TOPIC; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; YOUNG ADULT;

EID: 79959799979     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0411-6     Document Type: Article

References (31)

1. Longstreth WT, Dennis LK, McGuire VM (1993) Epidemiology of intracranial meningiomas. Cancer 72:639-648
2. Louis DN, Scheithauer BW, Budka B, von Deimling A, Kepes JJ (2000) Meningiomas. In: Kleihues P, Cavenee WK (eds) Pathology and genetics of tumours of the nervous system: World Health Organisation classification of tumours. IARC Press, Lyon, pp 176-184
3. Durand A, Labrousse F, Jouvet A, Bauchet L, Kalamaridès M, Menei P, Deruty R, Moreau JJ, Fèvre-Montange M, Guyotat J (2009) WHO grade II and III meningiomas: a study of prognostic factors. J Neurooncol 95(3):367-375
4. Hug EB, Devries A, Thornton AF et al (2000) Management of atypical and malignant meningiomas: role of high-dose, 3D-conformal radiation therapy. J Neurooncol 48(2):151-160
5. Black PM, Carroll R, Glowacka D, Riley K, Dashner K (1994) Platelet-derived growth factor expression and stimulation in human meningiomas. J Neurosurg 81(3):388-393 (Pubitemid 24267646)
6. Lamszus K, Lengler U, Schmidt NO, Stavrou D, Ergün S, Westphal M (2000) Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy. Neurosurgery 46(4):938-947
7. Ho DM, Hsu CY, Ting LT, Chiang H (2002) Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma. Cancer 94(5):1538-1547 (Pubitemid 34212649)
8. Perry A, Louis DN, Scheithauer BW, Budka H, von Diemling A (2007) Meningiomas. In: Louis DN, Ohgaki H, Wiestler OD, Cavanee WK (eds) World Health Organization classification of tumours of the central nervous system, 4th edn. IARC, Lyon, pp 164-172
9. Deng G, Curriden SA, Hu G, Czekay RP, Loskutoff DJ (2001) Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin. J Cell Physiol 189(1):23-33
10. Bajou K (2002) Role of PAI-1 plasminogen activator inhibitor in tumor invasion and angiogenesis. Bull Mem Acad R Med Belg 157(5-6):313-318
11. Bindal AK, Hammoud M, Shi WM, Wu SZ, Sawaya R, Rao JS (1994) Prognostic significance of proteolytic enzymes in human brain tumors. J Neurooncol 22(2):101-110
12. Sawaya R, Yamamoto M, Ramö OJ, Shi ML, Rayford A, Rao JS (1995) Plasminogen activator inhibitor-1 in brain tumors: relation to malignancy and necrosis. Neurosurgery 36:375-380
13. Arai Y, Kubota T, Nakagawa T, Kabuto M, Sato K, Kobayashi H (1998) Production of urokinase-type plasminogen activator (u-PA) and plasminogen activator inhibitor-1 (PAI-1) in human brain tumours. Acta Neurochirurgica 140:377-385
14. Kondraganti S, Gondi CS, McCutcheon I et al (2006) RNAi-mediated downregulation of urokinase plasminogen activator and its receptor in human meningioma cells inhibits tumor invasion and growth. Int J Oncol 28(6):1353-1360
15. Pakneshan P, Tetu B, Rabbani SA (2004) Demethylation of urokinase promoter as a prognostic marker in patients with breast carcinoma. Clinical Cancer Res 10:3035-3041 (Pubitemid 38619680)
16. Pakneshan P, Xing RH, Rabbani SA (2003) Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo. FASEB J 17(9):1081-1088 (Pubitemid 36676394)
17. Irigoyen JP, Munoz-Canoves P, Montero L, Koziczak M, Nagamine Y (1999) The plasminogen activator system: biology and regulation. Cell Mol Life Sci 56:104-132 (Pubitemid 29471930)
18. Webb DJ, Nguyen DH, Gonias SL (2000) Extracellular signal-regulated kinase functions in the urokinase receptor-dependent pathway by which neutralization of low density lipoprotein receptor-related protein promotes fibrosarcoma cell migration and matrigel invasion. J Cell Sci 113:123-134 (Pubitemid 30066339)
19. Jo M, Thomas KS, Somlyo AV, Somlyo AP, Gonias SL (2002) Cooperativity between the Ras-ERK and Rho-Rhi kinase pathways in urokinase-type plaminogen activator-stimulated cell migration. J Biol Chem 277(14):12479-12485 (Pubitemid 34952823)
20. Blasi F (2001) u-PA and cell migration: urokinase receptor as a ligand for a chemotactic G-protein-coupled receptor. Haemostasis 31:59
21. Degryse B, Orlando S, Resnati M, Rabbani SA, Blasi F (2001) Urokinase/urokinase receptor and vitronectin/alpha (v) beta (3) integrin induce chemotaxis and cytoskeleton reorganization through different signaling pathways. Oncogene 20:2032-2043
22. Andeasen PA, Egelund R, Petersen HH (2000) The plasminogen activation system in tumor growth, invasion and metastasis. Cell Mol Life Sci 57:25-40 (Pubitemid 30105328)
23. Siddique K, Yanamandra N, Gujrati M, Dinh D, Rao JS, Olivero W (2003) Expression of matrix metalloproteinases, their inhibitors and urokinase plasminogen activator in human meningiomas. Int J Oncol 22:289-294
24. Nagashima G, Fujimoto T, Suzuki R, Asai J, Itokawa H, Noda M (2006) Dural invasion of meningioma: a histological and immunohistochemical study. Brain Tumor Pathol 23(1):13-17 (Pubitemid 44576306)
25. Harbeck N, Schmitt M, Paepke S, Allgayer H, Kates RE (2007) Tumor-associated proteolytic factors uPA and PAI-1: critical appraisal of their clinical relevance in breast cancer and their integration into decision-support algorithms. Crit Rev Clin Lab Sci 44(2):179-201
26. Pappot H, Pedersen AN, Brünner N, Christensen IJ (2006) The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: relation to prognosis. Lung Cancer 51(2):193-200 (Pubitemid 43144362)
27. Pedersen H, Brünner N, Francis D et al (1994) Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 154(17):4671-4675 (Pubitemid 24276492)
28. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3(6):415-428 (Pubitemid 34587077)
29. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP (1998) Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72:141-196 (Pubitemid 27435555)
30. Semmler A, Simon M, Moskau S, Linnebank M (2008) Polymorphisms of methionine metabolism and susceptibility to meningioma formation: laboratory investigation. J Neurosurg 108(5):999-1004 (Pubitemid 351656849)
31. Kargiotis O, Chetty C, Gogineni V et al (2008) uPA/uPAR down regulation inhibits radiation-induced migration, invasion and angiogenesis in IOMM-Lee meningioma cells and decreases tumor growth in vivo. Int J Oncol 33(5):937-947